07Sep 2024
Combined PPV and Medication Therapy Enhances Vision in Submacular Hemorrhage

Combined PPV and Medication Therapy Enhances Vision in Submacular Hemorrhage

In a study of 14 patients with submacular hemorrhage (SMH), Pars Plana Vitrectomy (PPV) combined with low-dose recombinant tissue plasminogen activator (rt-PA) and intravitreal Conbercept was evaluated. Significant improvement in best-corrected visual acuity (BCVA) was observed at 7 days, 1 month, 3 months, 4 months, and 6 months post-treatment, with BCVA reaching a peak improvement at 6 months. Complete resolution of subfoveal hemorrhage was achieved in all cases, with hemorrhage absorption within one month and regression by 3 months. The treatment did not cause rt-PA-related retinal toxicity, although two cases of age-related macular degeneration developed discoid scars. This combined approach shows promise in improving vision and anatomical outcomes in SMH therapy.

  • #ophthalmology

Like

Save

Share